LONG-TERM EXPLORATORY ANALYSIS: mOS of ~30 months from start of 1L platinum-containing chemotherapy8
LIMITATIONS: This is an exploratory,
post hoc analysis of OS data, inclusive
of platinum-containing chemotherapy
(4-6 cycles), treatment-free interval
(4-10 weeks, per trial protocol), randomized
study treatment with BAVENCIO + BSC or BSC
alone, and subsequent therapy. This analysis
only includes patients who did not progress on
first-line platinum-containing chemotherapy
and subsequently enrolled in the JAVELIN
Bladder 100 trial. Safety data are not available
pre-randomization. No conclusions can be
drawn from this OS analysis.
1L=first-line; BSC=best supportive care;
HR=hazard ratio; mOS=median OS.
